HUP9801704A2 - A protein tirozin-kináz által mediált sejtproliferáció gátlására szolgáló pirido[2,3-d]pirimidinek és ezeket tartalmazó gyógyszerkészítmények - Google Patents
A protein tirozin-kináz által mediált sejtproliferáció gátlására szolgáló pirido[2,3-d]pirimidinek és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP9801704A2 HUP9801704A2 HU9801704A HUP9801704A HUP9801704A2 HU P9801704 A2 HUP9801704 A2 HU P9801704A2 HU 9801704 A HU9801704 A HU 9801704A HU P9801704 A HUP9801704 A HU P9801704A HU P9801704 A2 HUP9801704 A2 HU P9801704A2
- Authority
- HU
- Hungary
- Prior art keywords
- tyrosine kinase
- protein tyrosine
- pyrido
- pyrimidines
- nr5r6
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title abstract 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 2
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical class 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000002466 imines Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány a prőtein tirőzin-kináz (PTK) által mediált sejtprő-liferáció gátlására, közelebbről piridő[2,3-d]pirimidinekre és avegyületeknek a sejtprőliferáció gátlásában, illetve a prőteintirizin-kináz enzimatikűs aktivitásának gátlásában történőfelhasználására vőnatkőzik A találmány szerinti vegyületek ésgyógyászatilag elfőgadható sóik általánős képletében X iminő-, acil-iminő-csőpőrt, őxigén- vagy kénatőm, R1 -NR3R4, -S(O)0, 1 vagy 2-R3 vagy -OR3, R2, R3 és R4 hidrőgénatőm, -(CH2)nPh, ahől Ph adőtt esetben szűbsztitűált fenilcsőpőrt, és n 0, 1, 2 vagy 3, adőtt esetben szűbsztitűált heterőarőmás,ciklőalkil-, alkanőil-, alkil-, alkenil- vagy alkinilcsőpőrt, R4 tővábbi jelentése -C(=O)R3, -C(=O)OR3, -SO2R3, -SO2NR5R6, -C(=O)NR5R6, -C(=S)NR5R6, -C(=NH)R3, -C(=NH)NR5R6, valamint R3 és R4 azzal a nitrőgéatőmmal, amelyhez kapcsőlódnak, adőtt esetbenegy-hárőm heterőatőmőt tartalmazó gyűrűt képeznek, és Ar adőtt esetben szűbsztitűált fenil- vagy heterőarőmás csőpőrt. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/433,294 US5620981A (en) | 1995-05-03 | 1995-05-03 | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US08/611,279 US5733914A (en) | 1995-05-03 | 1996-04-03 | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9801704A2 true HUP9801704A2 (hu) | 1998-11-30 |
HUP9801704A3 HUP9801704A3 (en) | 1999-03-01 |
Family
ID=27029804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9801704A HUP9801704A3 (en) | 1995-05-03 | 1996-04-26 | Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation and medicaments containing them |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0823908B1 (hu) |
JP (1) | JP3885116B2 (hu) |
CN (1) | CN1083452C (hu) |
AT (1) | ATE344263T1 (hu) |
AU (1) | AU713727B2 (hu) |
BG (1) | BG62617B1 (hu) |
CA (1) | CA2214219C (hu) |
CZ (1) | CZ288160B6 (hu) |
DE (1) | DE69636671T2 (hu) |
EA (1) | EA000897B1 (hu) |
EE (1) | EE03770B1 (hu) |
ES (1) | ES2274526T3 (hu) |
GE (1) | GEP20002032B (hu) |
HU (1) | HUP9801704A3 (hu) |
IL (1) | IL117923A (hu) |
MX (1) | MX9706529A (hu) |
NO (1) | NO310110B1 (hu) |
NZ (1) | NZ307021A (hu) |
PL (1) | PL184093B1 (hu) |
SK (1) | SK283952B6 (hu) |
WO (1) | WO1996034867A1 (hu) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW321649B (hu) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
DE69613367T2 (de) * | 1995-04-27 | 2002-04-18 | Astrazeneca Ab | Chinazolin derivate |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
EP1806348A3 (en) * | 1997-02-05 | 2008-01-02 | Warner-Lambert Company LLC | Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
AU749750B2 (en) * | 1997-02-05 | 2002-07-04 | Warner-Lambert Company | Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9716231D0 (en) * | 1997-07-31 | 1997-10-08 | Amersham Int Ltd | Base analogues |
EP1801112A1 (en) * | 1998-05-26 | 2007-06-27 | Warner-Lambert Company LLC | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
PL344248A1 (en) | 1998-05-26 | 2001-10-22 | Warner Lambert Co | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
HUP0104199A3 (en) * | 1998-10-23 | 2002-12-28 | Hoffmann La Roche | Substituted pyrimido pyrimidinone derivatives, pharmaceutical compositions containing the same, process for the preparation thereof and intermediates |
IL149230A0 (en) | 1999-10-21 | 2002-11-10 | Hoffmann La Roche | Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
ES2280247T3 (es) | 1999-10-21 | 2007-09-16 | F. Hoffmann-La Roche Ag | Heterociclos de nitrogeno biciclicos heteroalquilamino sustituidos como inhibidores de proteinas de quinasa p38. |
ES2306306T3 (es) | 1999-11-05 | 2008-11-01 | Astrazeneca Ab | Nuevos derivados de quinazolina. |
US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
WO2001042243A2 (en) * | 1999-12-08 | 2001-06-14 | Advanced Medicine, Inc. | Protein kinase inhibitors |
AU2001278908A1 (en) | 2000-08-04 | 2002-02-18 | Warner Lambert Company | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin 7-ones |
BR0113037A (pt) | 2000-08-04 | 2004-01-20 | Warner Lambert Co | Processo para preparação de 2-(4-piridil) amino-6-dialquilox fenil-pirido[2,3-d] pirimidin-7-onas |
US6506749B2 (en) | 2000-08-31 | 2003-01-14 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (I) |
CA2420122A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines |
WO2002018380A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
US6518276B2 (en) | 2000-08-31 | 2003-02-11 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (II) |
DK1361880T3 (da) | 2001-02-12 | 2006-01-23 | Hoffmann La Roche | 6-substituerede pyrido-pyrimidiner |
IL162838A0 (en) | 2002-01-04 | 2005-11-20 | Univ Rockefeller | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders |
KR20060111716A (ko) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 |
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
ATE374201T1 (de) | 2002-08-06 | 2007-10-15 | Hoffmann La Roche | 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase |
CA2502970A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
CN100420687C (zh) * | 2002-12-20 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物 |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
CA2542105C (en) * | 2003-10-08 | 2011-08-02 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
DK1685131T3 (da) | 2003-11-13 | 2007-07-09 | Hoffmann La Roche | Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner |
CA2555724A1 (en) * | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
WO2005105097A2 (en) * | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
WO2006021547A1 (de) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
FR2887882B1 (fr) | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
CA2622725A1 (en) * | 2005-09-14 | 2007-03-22 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
CN102746298A (zh) * | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
US8044062B2 (en) * | 2005-10-07 | 2011-10-25 | Exelixis, Inc. | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha |
FR2896246B1 (fr) * | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
EP1981886B1 (en) | 2006-01-31 | 2009-08-12 | F.Hoffmann-La Roche Ag | 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
US20080032989A1 (en) * | 2006-05-31 | 2008-02-07 | Robinson William H | Method of treating inflammatory diseases using tyroskine kinase inhibitors |
KR101099926B1 (ko) | 2006-09-15 | 2011-12-28 | 화이자 프로덕츠 인코포레이티드 | 피리도 (2,3-d) 피리미디논 화합물 및 이의 pi3 억제제로서의 용도 |
EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
FR2910813B1 (fr) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
US20100150827A1 (en) * | 2007-04-11 | 2010-06-17 | Exelixis, Inc | Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer |
US20100209340A1 (en) * | 2007-04-11 | 2010-08-19 | Buhr Chris A | Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer |
EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
WO2010039740A1 (en) | 2008-09-30 | 2010-04-08 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
WO2010071846A2 (en) * | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
US8372970B2 (en) | 2009-10-09 | 2013-02-12 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders |
FR2955109B1 (fr) | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
WO2011100319A1 (en) | 2010-02-09 | 2011-08-18 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
KR20220031732A (ko) | 2011-03-04 | 2022-03-11 | 뉴젠 세러퓨틱스 인코포레이티드 | 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 |
JP2014513079A (ja) * | 2011-04-08 | 2014-05-29 | アフラクシス・ホールディングス・インコーポレイテッド | 神経系疾患及び癌の治療のための8−エチル−6−(アリール)ピリド[2,3−d]ピリミジン−7(8h)−オン |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
NZ703495A (en) * | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
US9493454B2 (en) | 2012-09-26 | 2016-11-15 | Tolero Pharmaceuticals, Inc. | Multiple kinase pathway inhibitors |
WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
WO2015061572A1 (en) | 2013-10-25 | 2015-04-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
JP2022533182A (ja) * | 2019-05-16 | 2022-07-21 | ユニバーシティー オブ ヒューストン システム | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
KR102329720B1 (ko) * | 2019-08-30 | 2021-11-23 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체 |
CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
WO2023177356A2 (en) * | 2022-03-18 | 2023-09-21 | Engine Biosciences Pte. Ltd. | Compounds and method for pkmyt1 inhibition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1171218A (en) * | 1967-11-09 | 1969-11-19 | Parke Davis & Co | New Heterocyclic Amine Compounds and Methods for their Production |
AU658646B2 (en) * | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
FR2706898B1 (hu) * | 1993-06-25 | 1995-09-08 | Union Pharma Scient Appl | |
ES2146782T3 (es) * | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
-
1996
- 1996-04-16 IL IL11792396A patent/IL117923A/xx not_active IP Right Cessation
- 1996-04-26 CZ CZ19973275A patent/CZ288160B6/cs not_active IP Right Cessation
- 1996-04-26 JP JP53337296A patent/JP3885116B2/ja not_active Expired - Fee Related
- 1996-04-26 AU AU55769/96A patent/AU713727B2/en not_active Ceased
- 1996-04-26 MX MX9706529A patent/MX9706529A/es not_active IP Right Cessation
- 1996-04-26 EE EE9700274A patent/EE03770B1/xx not_active IP Right Cessation
- 1996-04-26 CN CN96193678A patent/CN1083452C/zh not_active Expired - Fee Related
- 1996-04-26 EP EP96913175A patent/EP0823908B1/en not_active Expired - Lifetime
- 1996-04-26 NZ NZ307021A patent/NZ307021A/en unknown
- 1996-04-26 HU HU9801704A patent/HUP9801704A3/hu unknown
- 1996-04-26 DE DE69636671T patent/DE69636671T2/de not_active Expired - Lifetime
- 1996-04-26 GE GEAP19964010A patent/GEP20002032B/en unknown
- 1996-04-26 PL PL96323089A patent/PL184093B1/pl not_active IP Right Cessation
- 1996-04-26 CA CA002214219A patent/CA2214219C/en not_active Expired - Fee Related
- 1996-04-26 ES ES96913175T patent/ES2274526T3/es not_active Expired - Lifetime
- 1996-04-26 SK SK1410-97A patent/SK283952B6/sk unknown
- 1996-04-26 AT AT96913175T patent/ATE344263T1/de not_active IP Right Cessation
- 1996-04-26 EA EA199700356A patent/EA000897B1/ru not_active IP Right Cessation
- 1996-04-26 WO PCT/US1996/005819 patent/WO1996034867A1/en active IP Right Grant
-
1997
- 1997-10-29 BG BG102003A patent/BG62617B1/bg unknown
- 1997-10-31 NO NO19975033A patent/NO310110B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9801704A2 (hu) | A protein tirozin-kináz által mediált sejtproliferáció gátlására szolgáló pirido[2,3-d]pirimidinek és ezeket tartalmazó gyógyszerkészítmények | |
HUP0001507A2 (hu) | Pirrolo [2,3-d] pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
AP2002002455A0 (en) | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. | |
NZ508268A (en) | Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation | |
HUP9901820A2 (hu) | 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
TR200100917T2 (tr) | Aril ve heteroaril sübstitüentli heteroksiklik üreler kullanılarak RAF kinazın inhibe edilmesi | |
ES2196396T3 (es) | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. | |
EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
TR200201638T2 (tr) | Yeni imidazo[1,3,5]triazinonlar ve kullanımları | |
DK1123296T3 (da) | Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse | |
EE05289B1 (et) | Türosiinkinaaside pöördumatud inhibiitorid, farmatseutiline kompositsioon, kasutamine | |
HUP0103386A2 (hu) | Kinazolinszármazékok alkalmazása JAK 3 inhibitor hatású gyógyszerkészítmények előállítására | |
HUP0004807A2 (hu) | Vérlemezkéből származó növekedési faktort és/vagy P56lck tirozin kinázokat gátló hatású kinolin- és kinoxalin-vegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
MX9707453A (es) | Derivados de quinazolina. | |
CA2296031A1 (en) | Novel spiroazabicyclic heterocyclic compounds | |
CA2282277A1 (en) | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists | |
ATE291018T1 (de) | Pyrazol verbindungen und ihre verwendung | |
TR200402342T4 (tr) | 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri | |
ES2002012A6 (es) | Procedimiento para preparar (1,2,4)triazol (1,5-c)pirimidinas e-fusionadas | |
TR200402588T3 (tr) | N-[3-(3-siyanopirazolo[1,5-A]pirimidin-7-il)fenil]-N- etilasetamidin(zaleplon) üretim işlemi | |
TW200505926A (en) | 1,4-diazabicyclo [3.2.2] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof | |
AU8148387A (en) | Fused heterocyclic tetrahydroaminoquinolinols and related compounds, a process for their preparation and their use as medicaments | |
NZ322227A (en) | Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase | |
EP1144393A3 (en) | Heterocyclic derivatives and their use as integrin inhibitor | |
ATE238274T1 (de) | Naphthalin derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |